WSJ -- Teva Pharmaceutical Industries Ltd. said Tuesday its first-quarter net profit surged, lifted by strong sales of flagship multiple-sclerosis drug Copaxone and its neurological treatment Azilect, as the Israeli generic-drug maker forecast further expansion throughout the year.
